Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03381274 · ClinicalTrials.gov registry record · Phase 1

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by MedImmune.

Active
Registry status
Phase 1
Development phase
43
Enrollment target
13
Study locations

NCT03381274: Active Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by MedImmune.

NCT03381274 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 43 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (87% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03381274, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by MedImmune.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
43 participants
Enrollment target
13
Study locations

Study Summary

The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

Primary Outcome

A DLT was defined as \>= Grade 3 toxicity or adverse events (AE) occurred during DLT evaluation period which included any Grade 4 immune-mediated (immune nature) AE, anemia, thrombocytopenia (present \> 4 days), or neutropenia (present \> 4 days); \>= Grade 3 colitis or pneumonitis or interstitial lung disease (ILD); \>= Grade 3 nausea, vomiting, or diarrhea (not resolved to \<= Grade 2 in 3 days); Grade 2 pneumonitis or ILD (not resolved to \<= Grade 1 in 3 days); Grade 3 thrombocytopenia with

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Osimertinib
  • BIOLOGICAL Oleclumab
  • DRUG AZD4635

Study Locations (13)

Other

  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Taichung

California

  • Research Site - La Jolla
  • Research Site - San Francisco

Colorado

  • Research Site - Aurora

Connecticut

  • Research Site - New Haven

Georgia

  • Research Site - Atlanta

Illinois

  • Research Site - Chicago

Maryland

  • Research Site - Baltimore

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2018-05-08
Est. Completion 2026-04-16
Phase Phase 1
MedImmune

210 total trials

What the registry record for NCT03381274 still lists

NCT03381274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.

NCT03381274 lists 13 locations in 9 states (Other, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT03381274 about?

NCT03381274 is a clinical study titled "Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study". The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

What is the current status of trial NCT03381274?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2018-05-08. Estimated completion is 2026-04-16.

What conditions does trial NCT03381274 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT03381274?

The interventions under investigation include: Osimertinib (DRUG), Oleclumab (BIOLOGICAL), AZD4635 (DRUG).

Who is sponsoring clinical trial NCT03381274?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03381274 being conducted?

This trial has 13 study locations across California, Colorado, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03381274's enrollment target sits among peer trials

43 97th of 130 higher than 33 of 130 other Carcinoma, Non-Small Cell Lung trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03381274, the US trial registry maintained by the National Library of Medicine. NCT03381274 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.